Details of the Drug

General Information of Drug (ID: DM830EN)

Drug Name
NEO-201
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Drug Type
Antibody
Cross-matching ID
TTD ID
D7K5XP

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Biliary glycoprotein 1 (CEACAM1) TTA9CK4 CEAM1_HUMAN Inhibitor [2]
Carcinoembryonic antigen CEA (CD66e) TTY6DTE CEAM5_HUMAN Inhibitor [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Solid tumour/cancer
ICD Disease Classification 2A00-2F9Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Carcinoembryonic antigen CEA (CD66e) DTT CEACAM5 6.68E-91 0.29 1.07
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT03476681) QUILT-3.017: Study of NEO-201 in Solid Tumors. U.S. National Institutes of Health.
2 The Monoclonal Antibody NEO-201 Enhances Natural Killer Cell Cytotoxicity Against Tumor Cells Through Blockade of the Inhibitory CEACAM5/CEACAM1 Immune Checkpoint Pathway. Cancer Biother Radiopharm. 2020 Apr;35(3):190-198.